VIDEO: 'Potentially practice-changing' results from SWOG S1826 trial a highlight of ASCO
Click Here to Manage Email Alerts
In this video, Joshua Brody, MD, discussed the results of the SWOG S1826 trial of nivolumab vs. brentuximab vedotin in advanced-stage classic Hodgkin lymphoma, which were presented at ASCO Annual Meeting.
“This was a very ambitious trial, to take what I think is already very good standard of care — brentuximab plus AVD chemotherapy for front-line treatment of advanced-stage lymphoma — and to try and beat it,” Brody, director of the lymphoma immunotherapy program at The Tisch Cancer Institute at Mount Sinai, said.
Brody said that despite nivolumab (Opdivo, Bristol Myers Squibb) being an incredibly effective therapy, he was still unsure that it would beat brentuximab (Adcetris, Seagen) plus AVD, which he said demonstrated “amazing results” in the ECHELON-1 trial.
“I was a little skeptical that you could beat a result that was already so good, and the exciting answer was it seems like we can,” he said.
Reference :
- Herrera AF, et al. Abstract LBA4. Presented at: ASCO Annual Meeting; June 2-6, 2022; Chicago.
Collapse
Read more about
Click Here to Manage Email Alerts